Source:http://linkedlifedata.com/resource/pubmed/id/20854698
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2011-1-10
|
| pubmed:abstractText |
Lactoferrin (LF) is a multifunctional glycoprotein in mammalian milk. In a previous report, we showed that enteric-coated bovine LF tablets can decrease visceral fat accumulation, hypothesising that the enteric coating is critical to the functional peptides reaching the visceral fat tissue and exerting their anti-adipogenic activity. The aim of the present study was to assess whether ingested LF can retain its anti-adipogenic activity. We therefore investigated the effects of LF and LF treated with digestive enzymes (the stomach enzyme pepsin and the small intestine enzyme trypsin) on lipid accumulation in pre-adipocytes derived from the mesenteric fat tissue of male Sprague-Dawley rats. Lipid accumulation in pre-adipocytes was significantly reduced by LF in a dose-dependent manner and was associated with reduction in gene expression of CCAAT/enhancer binding protein delta, CCAAT/enhancer binding protein alpha and PPAR? as revealed by DNA microarray analysis. Trypsin-treated LF continued to show anti-adipogenic action, whereas pepsin-treated LF abrogated the activity. When an LF solution (1000 mg bovine LF) was administered by gastric intubation to Sprague-Dawley rats, immunoreactive LF determined by ELISA could be detected in mesenteric fat tissue at a concentration of 14·4 ?g/g fat after 15 min. The overall results point to the importance of enteric coating for action of LF as a visceral fat-reducing agent when administered in oral form.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1475-2662
|
| pubmed:author |
pubmed-author:FujisakiChikakoC,
pubmed-author:IigoMasaakiM,
pubmed-author:KatoHisanoriH,
pubmed-author:LaineR ORO,
pubmed-author:MiyashitaKazuoK,
pubmed-author:MorishitaSatoruS,
pubmed-author:MurakoshiMichiakiM,
pubmed-author:NishinoHoyokuH,
pubmed-author:OhderaMotoyasuM,
pubmed-author:OnoTomojiT,
pubmed-author:SugiyamaKeikichiK,
pubmed-author:YoshidaToshihideT
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
105
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
200-11
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:20854698-Adipocytes,
pubmed-meshheading:20854698-Adipogenesis,
pubmed-meshheading:20854698-Adult Stem Cells,
pubmed-meshheading:20854698-Animals,
pubmed-meshheading:20854698-Cattle,
pubmed-meshheading:20854698-Female,
pubmed-meshheading:20854698-Humans,
pubmed-meshheading:20854698-Intra-Abdominal Fat,
pubmed-meshheading:20854698-Lactoferrin,
pubmed-meshheading:20854698-Lipid Metabolism,
pubmed-meshheading:20854698-Male,
pubmed-meshheading:20854698-Obesity, Abdominal,
pubmed-meshheading:20854698-Pepsin A,
pubmed-meshheading:20854698-Rats,
pubmed-meshheading:20854698-Rats, Sprague-Dawley,
pubmed-meshheading:20854698-Tablets, Enteric-Coated,
pubmed-meshheading:20854698-Tissue Distribution,
pubmed-meshheading:20854698-Trypsin
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Effects of pepsin and trypsin on the anti-adipogenic action of lactoferrin against pre-adipocytes derived from rat mesenteric fat.
|
| pubmed:affiliation |
Research and Development Headquarters, Lion Corporation, 100 Tajima, Odawara, Kanagawa 256-0811, Japan. tomoono@lion.co.jp
|
| pubmed:publicationType |
Journal Article,
In Vitro
|